Investor Alert

New York Markets Close in:

Market Pulse Archives

March 5, 2021, 7:55 a.m. EST

NIH stops clinical trials for two experimental antibody COVID-19 treatments

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    Vir Biotechnology Inc. (VIR)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The National Institutes of Health said Thursday that it stopped enrollment in two clinical trials evaluating experimental COVID-19 therapies after discovering they likely do not provide a benefit to hospitalized patients. The treatment candidates are GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +0.32% and Vir Biotechnology Inc.'s /zigman2/quotes/214486077/composite VIR +0.45% monoclonal antibody therapy and the privately held Brii Biosciences Inc.'s monoclonal antibody cocktail. Vir told investorson Thursday that the NIH had notified the company about stopping the trial. There were no safety concerns for either therapy. Over the past year, GSK's stock is down 20.0% and shares of Vir tumbled 9.4%, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.0022% has rallied 20.4%.

/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 36.16
+0.12 +0.32%
Volume: 3.23M
April 14, 2021 1:41p
P/E Ratio
12.41
Dividend Yield
5.54%
Market Cap
$88.31 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 45.08
+0.20 +0.45%
Volume: 469,153
April 14, 2021 1:41p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.74 billion
Rev. per Employee
$233,541
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,141.68
+0.09 +0.0022%
Volume: 1.12B
April 14, 2021 1:41p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.